July 27, 2012 — Virginia Hospital Center is among the few hospitals along the east coast to offer the new Calypso System featuring GPS for the Body technology and Beacon electromagnetic transponders for patients with certain types of cancer. This new technology provides accurate, precise and real-time tracking to keep radiation focused on the tumor resulting in fewer side effects and a better quality of life for the patient.

Using miniaturized, non-ionizing, non-radioactive implanted devices called Beacon transponders, the Calypso System continuously and accurately tracks the location of cancerous tumors. For example, these rice-sized Beacons are implanted into the prostate or prostatic bed during an outpatient procedure, and are then tracked with a 4-D localization and tracking system. If the prostate or tumor bed moves out of range during treatment, the radiation beam turns off until it comes back into range again.

The real-time position and motion information provided by the Calypso System offers objective reassurance that radiation treatment is delivered precisely to the prescribed target, not to surrounding healthy tissue.

While radiation to the pelvic area can affect urinary, bowel and sexual function, research has shown that patients treated with Calypso had significantly fewer side effects in bowel urgency and frequency, fecal incontinence and urinary irritation. They also had fewer sexual side effects. Calypso technology allows the radiation oncologist to safely and maximally cover cancerous areas while minimizing normal tissue exposure to radiation.

Studies have also shown that patients who have undergone the Calypso procedure versus other similar treatments, have lived longer, healthier lives. The Calypso's GPS for the Body is the only U.S. Food and Drug Administration (FDA)-approved technology to track tumors in real time. Calypso can be used in primary radiation treatment or as an adjunctive treatment to surgery.

For more information: www.virginiahospitalcenter.com


Related Content

News | Artificial Intelligence

March 28, 2024 — As artificial intelligence (AI) makes its way into cancer care – and into discussions between ...

Time March 28, 2024
arrow
News | Prostate Cancer

March 27, 2024 — A minimally invasive treatment using MRI and transurethral ultrasound instead of surgery or radiation ...

Time March 27, 2024
arrow
Videos | Radiation Oncology

In the conclusion of this 3-part video series on recent advancements in diagnostic radiology, current editorial advisory ...

Time March 19, 2024
arrow
News | Breast Imaging

March 18, 2024 — QT Imaging Holdings, Inc., a medical device company engaged in research, development, and ...

Time March 18, 2024
arrow
Feature | Radiation Oncology | By Christine Book

Appreciating the considerable advances in the clinical application of artificial intelligence (AI) within healthcare ...

Time March 06, 2024
arrow
News | FDA

March 1, 2024 — Varian, a Siemens Healthineers company, announced that it has received 510(k) clearance from the U.S ...

Time March 01, 2024
arrow
News | Breast Imaging

February 22, 2024 — The FAST-Forward randomized trial from the UK found that ultrahypofractionated whole breast ...

Time February 22, 2024
arrow
News | Radiation Oncology

February 22, 2024 — The National Institutes of Health has launched a clinical trials network to evaluate emerging ...

Time February 22, 2024
arrow
News | Radiation Oncology

February 14, 2024 — Accuray Incorporated announced that the team at Quebec’s Montérégie Integrated Cancer Center, part ...

Time February 14, 2024
arrow
News | Radiation Oncology

February 12, 2024 — Radformation, a global pioneer in radiation oncology software solutions, is pleased to announce its ...

Time February 12, 2024
arrow
Subscribe Now